These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12943000)

  • 1. Neurodevelopment and mood stabilizers.
    Harwood AJ
    Curr Mol Med; 2003 Aug; 3(5):472-82. PubMed ID: 12943000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Search for a common mechanism of mood stabilizers.
    Harwood AJ; Agam G
    Biochem Pharmacol; 2003 Jul; 66(2):179-89. PubMed ID: 12826261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons.
    Di Daniel E; Mudge AW; Maycox PR
    Bipolar Disord; 2005 Feb; 7(1):33-41. PubMed ID: 15654930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters.
    Di Daniel E; Cheng L; Maycox PR; Mudge AW
    Mol Cell Neurosci; 2006; 32(1-2):27-36. PubMed ID: 16531065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inositol synthesis regulates the activation of GSK-3α in neuronal cells.
    Ye C; Greenberg ML
    J Neurochem; 2015 Apr; 133(2):273-83. PubMed ID: 25345501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics.
    Bachmann RF; Schloesser RJ; Gould TD; Manji HK
    Mol Neurobiol; 2005 Oct; 32(2):173-202. PubMed ID: 16215281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular cell biology of lithium.
    Williams R; Ryves WJ; Dalton EC; Eickholt B; Shaltiel G; Agam G; Harwood AJ
    Biochem Soc Trans; 2004 Nov; 32(Pt 5):799-802. PubMed ID: 15494019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure.
    Eickholt BJ; Towers GJ; Ryves WJ; Eikel D; Adley K; Ylinen LM; Chadborn NH; Harwood AJ; Nau H; Williams RS
    Mol Pharmacol; 2005 May; 67(5):1426-33. PubMed ID: 15687223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A common mechanism of action for three mood-stabilizing drugs.
    Williams RS; Cheng L; Mudge AW; Harwood AJ
    Nature; 2002 May; 417(6886):292-5. PubMed ID: 12015604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PtdIns(3,4,5)P(3) and inositol depletion as a cellular target of mood stabilizers.
    Teo R; King J; Dalton E; Ryves J; Williams RS; Harwood AJ
    Biochem Soc Trans; 2009 Oct; 37(Pt 5):1110-4. PubMed ID: 19754462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior.
    Shimshoni JA; Dalton EC; Jenkins A; Eyal S; Ewan K; Williams RS; Pessah N; Yagen B; Harwood AJ; Bialer M
    Mol Pharmacol; 2007 Mar; 71(3):884-92. PubMed ID: 17167030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons.
    Yasuda S; Liang MH; Marinova Z; Yahyavi A; Chuang DM
    Mol Psychiatry; 2009 Jan; 14(1):51-9. PubMed ID: 17925795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproate recovers the inhibitory effect of dexamethasone on the proliferation of the adult dentate gyrus-derived neural precursor cells via GSK-3β and β-catenin pathway.
    Boku S; Nakagawa S; Masuda T; Nishikawa H; Kato A; Takamura N; Omiya Y; Kitaichi Y; Inoue T; Kusumi I
    Eur J Pharmacol; 2014 Jan; 723():425-30. PubMed ID: 24211784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the molecular mechanisms underlying mood stabilizer treatments in bipolar disorder: Potential involvement of epigenetics.
    Pisanu C; Papadima EM; Del Zompo M; Squassina A
    Neurosci Lett; 2018 Mar; 669():24-31. PubMed ID: 27343410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can the mood stabilizer VPA limit both mania and depression?
    Cheng L; Lumb M; Polgár L; Mudge AW
    Mol Cell Neurosci; 2005 Jun; 29(2):155-61. PubMed ID: 15911340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity of mood stabilizer action on neuronal growth cones.
    Shaltiel G; Dalton EC; Belmaker RH; Harwood AJ; Agam G
    Bipolar Disord; 2007 May; 9(3):281-9. PubMed ID: 17430303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
    Gould TD; Picchini AM; Einat H; Manji HK
    Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mood stabilizers: protecting the mood...protecting the brain.
    Brunello N
    J Affect Disord; 2004 Apr; 79 Suppl 1():S15-20. PubMed ID: 15121343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid.
    Jonathan Ryves W; Dalton EC; Harwood AJ; Williams RS
    Bipolar Disord; 2005 Jun; 7(3):260-5. PubMed ID: 15898963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.